Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBT Margin (2016 - 2025)

Historic EBT Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to 50.46%.

  • Vanda Pharmaceuticals' EBT Margin fell 373600.0% to 50.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.52%, marking a year-over-year decrease of 410500.0%. This contributed to the annual value of 11.53% for FY2024, which is 148200.0% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' EBT Margin stood at 50.46%, which was down 373600.0% from 66.34% recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EBT Margin ranged from a high of 18.56% in Q2 2021 and a low of 74.67% during Q1 2025
  • Over the past 5 years, Vanda Pharmaceuticals' median EBT Margin value was 0.31% (recorded in 2023), while the average stood at 7.75%.
  • In the last 5 years, Vanda Pharmaceuticals' EBT Margin skyrocketed by 214100bps in 2023 and then tumbled by -648500bps in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' EBT Margin stood at 12.66% in 2021, then increased by 18bps to 14.91% in 2022, then crashed by -125bps to 3.67% in 2023, then tumbled by -233bps to 12.22% in 2024, then plummeted by -313bps to 50.46% in 2025.
  • Its last three reported values are 50.46% in Q3 2025, 66.34% for Q2 2025, and 74.67% during Q1 2025.